EP1461450A4 - Compositions t-bet et methodes d'utilisation associees - Google Patents

Compositions t-bet et methodes d'utilisation associees

Info

Publication number: EP1461450A4
Authority: EP; European Patent Office
Prior art keywords: methods; bet compositions; bet; compositions
Prior art date: 2001-12-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP02804492A

Other languages

German (de)

English (en)

Other versions

EP1461450A1 (fr

Inventor

Laurie H Glimcher

Susanne J Szabo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Harvard University

Original Assignee

Harvard University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-03

Filing date

2002-12-03

Publication date

2008-04-02

2002-12-03 Application filed by Harvard University filed Critical Harvard University

2004-09-29 Publication of EP1461450A1 publication Critical patent/EP1461450A1/fr

2008-04-02 Publication of EP1461450A4 publication Critical patent/EP1461450A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Toxicology (AREA)
Physical Education & Sports Medicine (AREA)

EP02804492A 2001-12-03 2002-12-03 Compositions t-bet et methodes d'utilisation associees Withdrawn EP1461450A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8264		1998-01-16
US10/008,264 US7393944B2 (en)	1999-06-02	2001-12-03	T-bet compositions and methods of use thereof
PCT/US2002/038514 WO2003048379A1 (fr)	2001-12-03	2002-12-03	Compositions t-bet et methodes d'utilisation associees

Publications (2)

Publication Number	Publication Date
EP1461450A1 EP1461450A1 (fr)	2004-09-29
EP1461450A4 true EP1461450A4 (fr)	2008-04-02

Family

ID=21730661

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP02804492A Withdrawn EP1461450A4 (fr)	2001-12-03	2002-12-03	Compositions t-bet et methodes d'utilisation associees

Country Status (6)

Country	Link
US (3)	US7393944B2 (fr)
EP (1)	EP1461450A4 (fr)
JP (2)	JP4533627B2 (fr)
AU (2)	AU2002357058C1 (fr)
CA (1)	CA2468701A1 (fr)
WO (1)	WO2003048379A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7393944B2 (en) *	1999-06-02	2008-07-01	President And Fellows Of Harvard College	T-bet compositions and methods of use thereof
AU2003304486A1 (en) *	2003-09-26	2005-04-14	Department Of Biogenic Amines, Polish Academy Of Sciences	Cells and methods useful in characterising the immunotoxic activity of xenobiotic substances
EP1889061A4 (fr)	2005-05-31	2009-06-03	Harvard College	Modulation du recrutement de lymphocytes t
WO2007056422A2 (fr) *	2005-11-07	2007-05-18	President And Fellows Of Harvard College	Modulation de la production d'il-2 par t-bet
EP1977003A4 (fr) *	2005-12-22	2009-11-11	Dermagene Oy	Méthodes et moyens relatifs à des maladies
WO2009042642A2 (fr) *	2007-09-24	2009-04-02	President And Fellows Of Harvard College	Compositions et méthodes de traitement et de prévention de la rectocolite hémorragique et du cancer du côlon
JP2012050440A (ja) *	2011-09-16	2012-03-15	Chiba Univ	ヒトＴｈ１／Ｔｈ２分化誘導の評価方法
US20220228114A1 (en) *	2019-05-29	2022-07-21	H. Lee Moffitt Cancer Center And Research Institute, Inc.	THERAPEUTIC T-CELLS WITH MODIFIED EXPRESSION OF T-BET, EOMES, AND c-MYB TRANSCRIPTION FACTORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0676469A3 (fr) *	1994-04-04	1998-03-25	Tadamitsu Kishimoto	Facteur de transcription APRF
WO1999011783A2 (fr)	1997-09-03	1999-03-11	Smithkline Beecham Plc	Polypeptides de boite t
US6207414B1 (en) *	1998-01-29	2001-03-27	The Board Of Regents Of The University Of Oklahoma	Tyrosylprotein sulfotransferases and methods of use thereof
US6031078A (en) *	1998-06-16	2000-02-29	Millennium Pharmaceuticals, Inc.	MTbx protein and nucleic acid molecules and uses therefor
US6037148A (en) *	1998-09-29	2000-03-14	Millennium Pharmaceuticals, Inc.	MTBX protein and nucleic acid molecules and uses therefor
US8048672B2 (en) *	1999-06-02	2011-11-01	President And Fellows Of Harvard College	T-bet compositions and methods of use thereof
DK1183355T3 (da)	1999-06-02	2006-03-13	Harvard College	T-BET-præparater og fremgangsmåder til fremstilling heraf
US7393944B2 (en) *	1999-06-02	2008-07-01	President And Fellows Of Harvard College	T-bet compositions and methods of use thereof
WO2003033680A2 (fr) *	2001-10-19	2003-04-24	Incyte Genomics, Inc.	Kinases et phosphatases
CA2595403A1 (fr) *	2005-01-20	2006-07-27	President And Fellows Of Harvard College	Modulation de l'engagement dans le lignage de th2 par t-bet

2001
- 2001-12-03 US US10/008,264 patent/US7393944B2/en not_active Expired - Lifetime
2002
- 2002-12-03 CA CA002468701A patent/CA2468701A1/fr not_active Abandoned
- 2002-12-03 JP JP2003549556A patent/JP4533627B2/ja not_active Expired - Fee Related
- 2002-12-03 EP EP02804492A patent/EP1461450A4/fr not_active Withdrawn
- 2002-12-03 AU AU2002357058A patent/AU2002357058C1/en not_active Ceased
- 2002-12-03 WO PCT/US2002/038514 patent/WO2003048379A1/fr active Application Filing
2005
- 2005-11-30 US US11/291,426 patent/US7365169B2/en not_active Expired - Lifetime
2008
- 2008-02-21 US US12/070,856 patent/US7745581B2/en not_active Expired - Fee Related
- 2008-08-29 AU AU2008207648A patent/AU2008207648A1/en not_active Withdrawn
2009
- 2009-08-31 JP JP2009200559A patent/JP2010011857A/ja not_active Withdrawn

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HWANG E.S. ET AL: "T Helper Cell Fate Specified by Kinase-Mediated Interaction of T-bet with GATA-3", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US LNKD- DOI:10.1126/SCIENCE.1103336, vol. 307, 21 January 2005 (2005-01-21), pages 430 - 433, XP003010210, ISSN: 0036-8075 *
KASHIWAKURA, J., ET AL: "Txk, A Nonreceptor Tyrosine Kinase of the Tec Family, Is Expressed in T Helper Type 1 Cells and Regulates Interferon gamma Production in Human T Lymphocytes", J. EXP. MED., vol. 190, no. 8, 8 October 1999 (1999-10-08), pages 1147 - 1154, XP002468312 *
SCHAEFFER, E.M., ET AL: "Requirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity", SCIENCE, vol. 284, 23 April 1999 (1999-04-23), pages 638 - 641, XP002468313 *
YANG, W.-C. AND OLIVE, D.: "Tec kinase is involved in transcriptional regulation of IL-2 and IL-4 in the CD28 pathway", EUR. J. IMMUNOL., vol. 29, 1999, pages 1842 - 1849, XP002468314 *
YIN, Z., ET AL: "T-Bet expression and Failure of GATA-3 Cross-Regulation Lead to Default Production of IFN-gamma by gamma-sigma T Cells", THE JOURNAL OF IMMUNOLOGY, vol. 168, 2002, pages 1566 - 1571, XP002468315 *

Also Published As

Publication number	Publication date
JP2010011857A (ja)	2010-01-21
AU2008207648A1 (en)	2008-09-25
WO2003048379A1 (fr)	2003-06-12
US7745581B2 (en)	2010-06-29
AU2002357058C1 (en)	2009-03-26
EP1461450A1 (fr)	2004-09-29
JP2005511056A (ja)	2005-04-28
US20080300384A1 (en)	2008-12-04
US7365169B2 (en)	2008-04-29
US20060084118A1 (en)	2006-04-20
US20030104528A1 (en)	2003-06-05
US7393944B2 (en)	2008-07-01
AU2002357058A1 (en)	2003-06-17
CA2468701A1 (fr)	2003-06-12
JP4533627B2 (ja)	2010-09-01
AU2002357058B2 (en)	2008-08-28

Publication	Publication Date	Title
EP1636250A4 (fr)	2010-11-03	Peptides autoassembles presentant des modifications et methodes d'utilisation des peptides
EP1610772A4 (fr)	2008-06-18	Substituts de retinoides et agonistes d'ospine et methodes d'utilisation correspondantes
FR16C1012I2 (fr)	2019-01-11	Utilisation therapeutique d'anticorps anti-cs1
DE60233192D1 (de)	2009-09-17	Hydrophobe und lipophobe zusammensetzung
EP1608318A4 (fr)	2009-07-29	Antagonistes cxcr4 et leurs procedes d'utilisation
EP1558444A4 (fr)	2010-10-13	Biomateriaux a base de soie et leurs methodes d'utilisation
ID30590A (id)	2002-01-03	Celana sekali pakai jenis-celana pendek
NO20016173D0 (no)	2001-12-18	Gipssammensetninger og fremgangsmåter ved fremstilling derav
FR12C0012I2 (fr)	2012-10-26	Combinaisons d'herbicides et de phytoprotecteurs
DE60134851D1 (de)	2008-08-28	Härtbare zusammensetzungen und kompatibilitätsmittel
EP1507541A4 (fr)	2009-06-03	Inhibiteurs et procedes d'utilisation de ceux-ci
NO20022334L (no)	2002-07-09	Ny sammensetning og anvendelse
EP1624935A4 (fr)	2009-07-08	Composites anti-adherence et methodes d'utilisation desdits composites
BRPI0208558A2 (pt)	2017-05-23	preparado de combinação de estrogênio-gestagênio e uso
DE60216254D1 (de)	2007-01-04	Acrylkautschukzusammensetzung und vulkanisat
EP1423399A4 (fr)	2008-05-07	Chelateurs d'hydroxypyridonate et d'hydroxypyrimidinone
EE05020B1 (et)	2008-06-16	Glburiidi ravimkoostis
AR028610A1 (es)	2003-05-14	Composiciones antitranspirantes y/o desodorantes
EP1466979A4 (fr)	2005-04-06	Lysyle oxydases d'origine fongique
EP1476150A4 (fr)	2007-07-04	Carboxyfullerenes et procedes d'utilisation de ceux-ci
EP1476159A4 (fr)	2006-03-01	Compositions et formulations de polymorphes de 9- nitrocamptothecine et procedes d'utilisation de ces derniers
EP1272111A4 (fr)	2004-10-06	Instruments chirurgicaux portatifs et omni-actionnables
DE60121951D1 (de)	2006-09-14	Charakterisierung nichtlinearen Verhaltens
DE60117771D1 (de)	2006-05-04	Fluorvinylether und copolymerzusammensetzungen davon
EP1817055A4 (fr)	2008-12-17	Compositions d'anticorps anti-ovr110 et methodes d'utilisation correspondantes

Legal Events

Date	Code	Title	Description
2004-08-13	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-09-29	17P	Request for examination filed	Effective date: 20040701
2004-09-29	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR
2004-09-29	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO
2008-04-02	A4	Supplementary search report drawn up and despatched	Effective date: 20080303
2008-11-26	17Q	First examination report despatched	Effective date: 20081024
2011-07-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2011-08-24	18D	Application deemed to be withdrawn	Effective date: 20110308